Immunization with two recombinant Bacillus Calmette-Guérin vaccines that combine the expression of multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast tumor growth in mice

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 9, 2010, Pages 1359-1367

  Yuan, Shifang ^a   Shi, Changhong ^b   Ling, Rui ^a   Wang, Ting ^a   Wang, Hui ^a   Han, Wei ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Anti tumor immunotherapy; Breast tumor; MUC1; Recombinant BCG vaccine; Variable number tandem repeat

Indexed keywords

BCG VACCINE; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MUCIN 1; RECOMBINANT VACCINE; MUC1 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; ELECTROPORATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; TANDEM REPEAT; TUMOR GROWTH; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; IMMUNOLOGY; MOUSE MUTANT; PATHOLOGY; TUMOR CELL LINE; VARIABLE NUMBER OF TANDEM REPEAT;

ANIMALS; BCG VACCINE; BREAST NEOPLASMS; CANCER VACCINES; CELL LINE, TUMOR; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, SCID; MINISATELLITE REPEATS; MUCIN-1; RECOMBINANT PROTEINS;

EID: 77955492913     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0787-x     Document Type: Article

References (26)

1. B Acres V Apostolopoulos JM Balloul, et al. 2000 MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines Cancer Immunol Immunother 48 588 594 10.1007/PL00006677 10.1007/PL00006677 1:CAS:528:DC%2BD3cXmsFSmtA%3D%3D 10630311
2. JD Ahlers IM Belyakov S Matsui, et al. 2001 Mechanisms of cytokine synergy essential for vaccine protection against viral challenge Int Immunol 13 897 908 10.1093/intimm/13.7.897 10.1093/intimm/13.7.897 1:CAS:528: DC%2BD3MXlsFOgtbg%3D 11431420
3. Apostolopoulos V, Pietersz GA, Tsibanis A et al. (2006) Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1. Breast Cancer Res 8:R27. doi: 10.1186/bcr1505
4. SE Baldus K Engelmann FG Hanisch 2004 MUC1 and the MUCs: a family of human mucins with impact in cancer biology Crit Rev Clin Lab Sci 41 189 231 10.1080/10408360490452040 10.1080/10408360490452040 1:CAS:528: DC%2BD2cXlslalt70%3D 15270554
5. RG Barletta B Snapper JD Cirillo, et al. 1990 Recombinant BCG as a candidate oral vaccine vector Res Microbiol 141 931 939 10.1016/0923-2508(90) 90132-A 10.1016/0923-2508(90)90132-A 1:STN:280:DyaK3Mzis12ktA%3D%3D 2101484
6. MA Chung Y Luo M O'Donnell, et al. 2003 Development and preclinical evaluation of a Bacillus Calmette-Guerin-MUC1-based novel breast cancer vaccine Cancer Res 63 1280 1287 1:CAS:528:DC%2BD3sXit1Sgtb8%3D 12649188
7. ML Disis H Bernhard FM Shiota, et al. 1996 Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines Blood 81 202 210
8. A Girling J Bartkova J Burchell, et al. 1989 A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas Int J Cancer 43 1072 1076 10.1002/ijc.2910430620 10.1002/ijc.2910430620 1:STN:280:DyaL1M3nslGrtg%3D%3D 2471698
9. J Gong D Chen M Kashiwaba, et al. 1997 Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells Nat Med 3 558 561 10.1038/nm0597-558 10.1038/nm0597-558 1:CAS:528:DyaK2sXivFOltLo%3D 9142127
10. RT Greenlee T Murray S Bolden, et al. 2000 Cancer statistics Cancer J. Clin 50 7 33 10.3322/canjclin.50.1.7 10.3322/canjclin.50.1.7 1:STN:280:DC%2BD3c7pvFWrug%3D%3D
11. MS Hanson GP Bansal S Langermann, et al. 1995 Efficacy and safety of live recombinant BCG vaccines Dev Biol Stand 84 229 236 1:STN:280: DyaK2MzhslCktA%3D%3D 7796958
12. CA Hunter SL Reiner 2000 Cytokines and T cells in host defense Curr Opin Immunol 12 413 418 10.1016/S0952-7915(00)00110-2 10.1016/S0952-7915(00)00110-2 1:CAS:528:DC%2BD3cXkvVyltLg%3D 10899023
13. Y Huo B Li YQ Zhang, et al. 2007 Pre-clinical safety evaluation of heat shock protein 65-MUC1 peptide fusion protein Regul Toxicol Pharmacol 49 63 74 10.1016/j.yrtph.2007.05.005 10.1016/j.yrtph.2007.05.005 1:CAS:528: DC%2BD2sXhtVWiu7vO 17600604
14. A Iwasaki BJ Stiernholm AK Chan, et al. 1997 Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines J Immunol 158 4591 4601 1:CAS:528:DyaK2sXjtFGnurc%3D 9144471
15. KG Kohlgraf AJ Gawron M Higashi, et al. 2004 Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1) Cancer Immunol Immunother 53 1068 1084 10.1007/s00262-004- 0557-1 10.1007/s00262-004-0557-1 1:CAS:528:DC%2BD2cXotlKgtrY%3D 15696607
16. S Koido M Kashiwaba D Chen, et al. 2000 Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA J Immunol 165 5713 5719 1:CAS:528:DC%2BD3cXot1Grsbw%3D 11067929
17. Y Kotera JD Fontenot G Pecher, et al. 1994 Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients Cancer Res 54 2856 2860 1:CAS:528:DyaK2cXktVKqsbs%3D 7514493
18. S North C Butts 2005 Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers Expert Rev Vaccines 4 249 257 10.1586/14760584.4.3.249 10.1586/14760584.4.3.249 1:CAS:528:DC%2BD2MXntVGrtrk%3D 16026241
19. RK Ramanathan KM Lee J McKolanis, et al. 2005 Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer Cancer Immunol Immunother 54 254 264 10.1007/s00262-004-0581-1 10.1007/s00262-004-0581-1 1:CAS:528: DC%2BD2MXjs1ahuw%3D%3D 15372205
20. C Rochlitz R Figlin P Squiban 2003 Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer J Gene Med 5 690 699 10.1002/jgm.397 10.1002/jgm.397 1:CAS:528:DC%2BD3sXnvVShtLo%3D 12898638
21. MM Soares V Mehta OJ Finn 2001 Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection J Immunol 166 6555 6563 1:CAS:528:DC%2BD3MXjvFartLk%3D 11359807
22. CK Stover VF de la Cruz TR Fuerst, et al. 1991 New use of BCG for recombinant vaccines Nature 351 456 460 10.1038/351456a0 10.1038/351456a0 1:CAS:528:DyaK3MXksVegtbo%3D 1904554
23. J Taylor-P JM Burchell T Plunkett, et al. 2002 MUC1 and the immunobiology of cancer J Mammary Gland Biol Neoplasia 7 209 221 10.1023/A:1020360121451 10.1023/A:1020360121451
24. RM Tempero ML VanLith K Morikane, et al. 1989 CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice J Immunol 161 5500 5506
25. WR Weiss KJ Ishii RC Hedstrom, et al. 1998 A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine J Immunol 161 2325 2332 1:CAS:528:DyaK1cXlslagtrg%3D 9725227
26. K Yamamoto T Ueno T Kawaoka, et al. 2005 MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer Anticancer Res 25 3575 3579 1:CAS:528:DC%2BD2MXps1Kgur0%3D 16101182